 
Document Type:  Statistical Analysis Plan  
Official Title:  A multicenter, randomized, placebo-controlled, parallel group, 
double blind, dose-finding Phase II trial to study the efficacy, safety,  pharmacokinetic and pharmacodynamic effects of the oral 
partial  adenosine A1 receptor agonist neladenoson bialanate over 
20 weeks in patients with chronic heart failure with reduced ejection fraction  
Study ID: [REMOVED] 
Document Date:  29 MAY 2018 
 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 1 of 39:
Title page
A multicenter, randomized, placebo -controlled, parallel group, double 
blind, dose -finding Phase II trial to study the efficacy, safety, 
pharmacok inetic and pharmacodynamic effects of the oral partial 
adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in 
patients with chronic heart failure with reduced ejection fraction
short title : PANTHEON
Bayer study drug Neladenoson bialanate / BAY 1067197
Study purpose: dose finding
Clinical study 
phase:IIb Date: 29MAY 2018
Study No.: BAY 1067197 / 15128 Version: 3.0
Author:
Confidential
The information provided in this document is strictly  confidential and is intended solely  
for the guidance of the clinical investigation.  Reproduction or disclosure of this 
document, whether in part or in full, to parties not associated with the clinical 
investigation or its use for an y other purpose without the prior written consent of the 
sponsor is not perm itted.
Throughout this document, symbols indicating proprietary names (®, TM) are not displayed.  Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.
This Statistical Analysis Plan is produced on a w ord-processing system and bears no signatures.
The approval of the Statistical Analysis Plan is documented in a separate Signature Document.
PPD
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 2 of 39:
Table of Contents
Title page ................................................................................................................................... 1
Abbreviations ............................................................................................................................ 4
1. Introduction ....................................................................................................................... 7
2. Study Objectives................................................................................................................ 7
3.Study Design ...................................................................................................................... 8
4. General Statistical Considerations .................................................................................. 9
4.1 General Principles ............................................................................................................ 9
4.2 Handling of Dropouts ...................................................................................................... 9
4.3 Handling of Missing Data.............................................................................................. 10
4.4 Interim Anal yses and Data Monitoring .......................................................................... 11
4.5 Data Rules ...................................................................................................................... 11
4.5.1 Baseline and Change from Baseline ........................................................................... 11
4.5.2 Repeated Measurements ............................................................................................. 12
4.5.3 Laboratory  Data Handling .......................................................................................... 12
4.5.4 Subgroup anal yses...................................................................................................... 12
4.6 Blind Review ................................................................................................................. 13
5.Analysis Sets ..................................................................................................................... 13
5.1 Assignment of anal ysis sets ........................................................................................... 13
6.Statistical Methodology ................................................................................................... 15
6.1 Population characteristics .............................................................................................. 15
6.1.1 Disposition of Subjects ............................................................................................... 15
6.1.2 Demographic and Baseline Characteristics ................................................................ 15
6.1.3 Medical history ........................................................................................................... 16
6.1.4 Prior and Concomitant Medications ........................................................................... 16
6.2 Efficacy .......................................................................................................................... 18
6.2.1 Primary  efficacy  variables and anal yses..................................................................... 18
6.2.1.1 Primary  efficacy  variables ....................................................................................... 18
6.2.1.2 Primary  anal ysis of primary  efficacy  variables ....................................................... 18
6.2.1.3 Secondary  anal ysis of primary  efficacy  variables ................................................... 23
6.2.1.4 Sensitivity  analy ses of primary  efficacy variables .................................................. 23
6.2.1.5 Additional analy sis of primary  efficacy  variables................................................... 24
6.2.2 Secondary  efficacy  variables and anal yses................................................................. 24
6.2.2.1 Secondary  efficacy  variables ................................................................................... 24
6.2.2.2 Primary  anal yses of secondary  efficacy  variables................................................... 24
6.2.2.3 Sensitivity  analy ses of secondary  efficacy  variables .............................................. 25
6.2.2.4 Additional analy ses of secondary  efficacy  variables .............................................. 25
6.2.3 Exploratory  efficacy  variables and analy ses............................................................... 25
6.3 Safety ............................................................................................................................. 26
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 3 of 39:
6.3.1 Extent of exposure ...................................................................................................... 26
6.3.2 Treatment Compliance ................................................................................................ 27
6.3.3 Adverse events ............................................................................................................ 27
6.3.4 Deaths ......................................................................................................................... 28
6.3.5 Clinical laboratory  evaluations ................................................................................... 28
6.3.6 AVIVO/HealthPatch monitoring ................................................................................ 29
6.3.7 Other safety  measures ................................................................................................. 29
6.4 Subgroup Analy sis......................................................................................................... 29
6.4.1 Subgroups ................................................................................................................... 29
6.4.2 Subgroup anal ysis of efficacy  variables ..................................................................... 29
6.4.3 Subgroup anal ysis of safety  variables......................................................................... 29
6.5 Pharmacokinetics/pharmacod ynamics ........................................................................... 30
6.6 Biomarker anal yses........................................................................................................ 30
7.Document history and changes in the planned statistical analysis ............................. 30
8.References ........................................................................................................................ 31
9.Appen dices ....................................................................................................................... 32
9.1 AVIVO device variable specification ............................................................................ 32
9.2 Echocardiograph y parameters ........................................................................................ 33
9.3 KCCQ Scoring ............................................................................................................... 34
9.3.1 Physical Limitation ..................................................................................................... 34
9.3.2 Symptom Stability ...................................................................................................... 34
9.3.3 Symptom Frequency ................................................................................................... 35
9.3.4 Symptom Burden ........................................................................................................ 35
9.3.5 Self-Efficacy ............................................................................................................... 36
9.3.6 Quality  of Life ............................................................................................................ 36
9.3.7 Social L imitation ........................................................................................................ 37
9.3.8 Total Sy mptom Score ................................................................................................. 37
9.3.9 Overall Summary  Score .............................................................................................. 37
9.3.10 Clinical Summary  Score ............................................................................................. 37
9.4 Combining inferences from multiple imputed data sets ................................................ 37
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 4 of 39:
Abbreviations
A1R A1 receptor
ACE angiotensin -converting enzy me
ACEi ACE inhibitor
AE(s) adverse event(s)
AF atrial fibrillation
ALT alanine aminotransferase
ARB(s) angiotensin receptor blocker(s)
ARNI(s) angiotensin receptor -neprily sin inhibitor(s)
AST aspartate aminotransferase
AUC area under the time -concentration curve
AV atrioventricular
BMI body  mass index
BNP b-type natriuretic peptide
BSA body  surface area
CHF chronic heart failure
Cmax maximum drug concentration in plasma
CO cardiac output
CRF case report form
CV cardiovascular
DMC Data Monitoring Committee
e.g. for example ( exempli gratia )
ECG electrocardiogram
eCRF electronic CRF
EF ejection fraction
eGFR estimated glomerular filtration rate
EQ-5D-5L EuroQol Group 5 -dimensional, 5 -level questionnaire
EU European Union
EWDT E-wave deceleration time
FAS full analy sis set
GFR glomerular filtration rate
GGT gamma glutam yl transpeptidase
HDL high-densit y lipoprotein
HF heart failure
HFpEF heart failure with preserved ejection fraction
HFrEF heart failure with reduced ejection fraction
HR heart rate
hs-TNT high sensitivity  troponin T
i.e. that is ( id est )
ICF informed consent form
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 5 of 39:
ICH International Conference on Harmonization
INR international normalized ratio
ITT intent -to-treat
IVSD interventricular septum diameter 
KCCQ Kansas City  cardiom yopathy questionnaire
LA left atrial
LAV LA volume
LAVI LA volume index
LDH lactate deh ydrogenase 
LDL low-density  lipoprotein
LV left ventricular
LVEDV LV end -diastolic volume
LVEDVI LVEDV index 
LVEF left ventricular ejection fraction
LVESV left ventricular end -systolic volume
LVESV I LVESV index
MAP mean arterial pressure
MCH mean corpuscular hemoglobin
MCHC MCH concentration
MCP multiple comparison procedures
MCV mean corpuscular volume
MedDRA Medical Dictionary  for Regulatory  Activities
mL milliliter
MRA mineralocorticoid receptor antagonist
NGAL neutrophil gelatinase -associated lipocalin
NONMEM non-linear mixed effect modeling
NT-proBNP N-terminal pro -hormone b -type natriuretic peptide
NYHA New York Heart Association
PASP pulmonary  artery  systolic pressure
PDV premature discontinuation visit
Pes end-systolic pressure
pg picogram
PK pharmacokinetic
PKS PK analy sis set
PP pulse pressure
PPS per-protocol set
PTT partial thromboplastin time
PWT posterior wall thickness
RV right ventricular
SAC systemic arterial compliance
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 6 of 39:
SAE(s) serious adverse event(s)
SAF safet y analysis set
SAP statistical analy sis plan
SBP systolic blood pressure
SV stroke volume
SVI SV index
TAPSE tricuspid annular plane systolic excursion
TD tissue Doppler
TPR total peripheral resistance
UACR urine albumin -to-creatinine ratio
US United States (of America)
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 7 of 39:
1. Introduction
Chronic heart failure (CHF) is a major public health problem characterized by  significant 
mortality , frequent hospitalizations, and poor quality  of life, with an overall prevalence that is 
increasing througho ut the world. HF carries a prognosis comparable to many  forms of cancer 
with a 5 -year survival rate of approximately 50% (1), which exceeds that of many  cancers ( 2). 
Frequent hospitalizations, along with other direct and indirect costs, also place an enormous 
financial burden on healthcare s ystems; more is spent annuall y in the US for the treatme nt of 
HF b y Medicare than on any other Medicare -covered condition ( 3).Upon hospitalization for 
HFrEF mortality  and re -hospitalization for HF remain high despite treatment wi th stable 
chronic HFrEF neurohumoral blockers, indicating that this does not fully  explore the 
complexity  of HF pathophy siology .Additionally , the repeated stepwise addition of 
hemody namicall y active medications raises tolerability  and safety  concerns (e.g . hypotension 
and brad ycardia) ( 4). 
Therefore, addressing the failing heart directly  and getting viable but not functional 
myocardium back to work might be a new option f or the development of the next generation 
of hemod ynamicall y silent HF drugs. In this context, neladenoson bialanate holds promise as 
a potentially  hemody namically  neutral therapy  for HF that could simultaneously  improve 
cardiom yocyte energetics, calcium h omeostasis, cardiac structure and function, and long -term 
clinical outcomes when added to background therapies.
Neladenoson bialanate (BAY 1067197, which is the free base of the h ydrochloride BAY 86 -
8901) is the pro -drug of the pharmacologicall y active com pound BAY 84 -3174, a highl y 
potent and selective non -adenosine like partial adenosine A1 receptor agonist suitable for 
once dail y oral use.
The main limitations of using full A1R agonists in cardiovascular indications such as HF are 
undesired cardiac effec ts, such as brady cardia and higher degree AV block as well as negative 
cardiac inotrop y and dromotropy. In contrast, preclinical data show that the partial adenosine 
A1R agonist neladenoson bialanate can be used to modulate and trigger primarily  favorable 
pharmacological responses for HF therap y and avoid undesired effects such as AV conduction 
abnormalities and higher degree AV Block. Nevertheless, based on the mode of action, there 
are theoretical concerns particularl y with regard to undesired effects, su ch as brad ycardia and 
higher degree AV block for an A1R agonist, which might be aggravated b y concomitant use 
of standard heart failure therap y.
The purpose of this clinical trial is to assess the safety , tolerability  and the pharmacokinetic 
and pharmacod ynamic response of 20 weeks’ treatment with neladenoson bialanate compared 
to placebo in patients with chronic HFrEF on standard therap y for HF and to find the optimal 
dose for a further Phase III trial.
This statistical analysis plan (SAP) is based on the Global Integrated Clinical Study Protocol BAY 
106-7197/15128 version 2.0, dated 17 FEB 2017. 
2. Study Objectives
The objective of the study is to find the optimal dose of neladenoson bialanate for the Phase 
III trial b y detecting and characterizing a significant dose -response relationship in the two 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 8 of 39:
primary  efficacy  endpoints, absolute change from baseline in LVEF and log -transformed NT -
proBNP at 20 weeks, in patients with chronic heart failure with reduced ejection fraction 
(HFrEF), and b y characterizing the safet y, tolerability  and pharmacody namic effects of the 
compound when given in addition to standard therapy  for HFrEF.
An exploratory  objective is to further assess pharmacokinetic paramete rs and blood and urine
biomarkers.
3. Study Design
Study  15128 is a randomized, double -blind, placebo -controlled, parallel group, multicenter, 
Phase II stud y. Figure 3–1 display s the overall study  design. 
Figure 3–1: Study design overview
Abbreviations: CV = cardiovascular; ICF = informed consent form; W = week
Approximately  384 patients from approximately  90 study  centers worldwide will be 
randomized to one of the active treatment d ose arms or placebo, in addition to standard of care 
heart failure therap y (for details see Section 7).
The study  will comprise a 1 -week run -in period, 20 -week treatment period, and a 6 -week 
follow -up period (27 weeks total).
Patients will have site visits at weeks -1, 0 (baseline), 4, 8, 12, 20 (end -
of-treatment visit) and 
24 (safet y follow -up visit). In addition, 2 phone calls at weeks 2 and 26 will be made to assess 
patients’ safet y, and one additional phone call - to remind the patients of AVIVO self-
application at Week 19. 
LVEF will be measured by  echocardiograph y at baseline and end of treatment, NT -proBNP 
will be measured at baseline, Week 4 and end of treatment. Safet y will be monitored 
throughout the stud y. PK samples will be taken from all patient s at dedicated time points. 

Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 9 of 39:
Additional biomarkers reflecting the pharmacod ynamic activity  of the drug will be examined, 
as well as candidate biomarkers that may  predict drug response.  
For detailed visit descriptions and rules for patients who discontinue study  treatment earlier, 
please see protocol Sections 9.1 and 9.2.
The anticipated duration of the study  as a whole is approximately  19 months: this includes an 
anticipated recruitment period of 13 months followed b y a run -in period of 1 week, a 
treatment period of 20 weeks and a follow -up period of 6 weeks after enrollment of the last 
patient into the trial.
A parallel group design was chosen to compare five different once -daily dose regimens and 
one placebo arm to find the best dose for Phase III. Placebo control is used to control for 
observer and subject bias, and randomization - to control for assignment bias. Based on Phase 
I data in health y volunteers and Phase II data on heart failure patients, a sequential dose 
escalation design was not deemed nece ssary  for neladenoson bialanate since the safet y profile 
of the compound could be verified in dose ranges up to 40 mg. Safet y of the subjects in this 
parallel stud y design will be closel y monitored b y an Data Monitoring Committee (DMC).
The end of the stud y as a whole will be reached as soon as the last visit of the last patient has 
occurred in all centers in all participating countries (EU and non -EU).
4. General Statistical Considerations
4.1 General Principles
The statistical evaluation will be performed b y usi ng the software package SAS version 9.2 or 
higher (SAS Institute I nc., Cary , NC, USA). Unless otherwise noted, data will be anal yzed by 
descriptive statistical methods: The number of data available and missing data, mean, standard 
deviation, minimum, quart iles, median, and maximum will be calculated for metric data. 
Frequency  tables will be generated for categorical data.
Definition of efficacy  and safet y endpoints, anal ysis strategies, structure of anal ysis datasets 
and lay out of anal ysis data display s are following Bay er AG standards: Neladenoson bialanate
Project Standards, the Therapeutic Area Cardiovascular Standards (TAS) and the Global 
Medical Standards (GMS), respectively . The given ordering reflects the priority  of the 
different standards, i.e. specifications of the latter ones have to be followed only  if not 
specified in standards mentioned before. Study -specific specifications may  be included in 
addition to the Project Standards, if needed.
4.2 Handling of Dropouts
A “dropout” is defined as a subject w ho has been randomized and discontinues study  
participation prematurel y for an y reason. Subjects withdrawn from stud y treatment will not be 
replaced. Refer to Section 6.4 in the Clinical Study Protocol for withdrawal of subjects from 
study .
See following chapters for more details on deriving efficacy  endpoints in case of missing data.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 10 of 39:
4.3 Handling of Missing Data
All missing or partial data will be presented in the patient data listing as they  are recorded in 
the eCRF. 
A number of descriptive anal yses will be performed to better understand missing data 
patterns. The frequency , proportion and the reasons for premature discontinuation of both the 
study  and study treatment will be reported. Kaplan -Meier plots for “time to e nd of study  
treatment (calculated as day s from first dose to the earliest date of stop medication , including 
premature stop of stud y medication and death , for the calculation all the subjects will be 
considered to have an event- stop of study  medication )” and “time to end of study ”(calculated 
from randomization to the earliest date of visit 9, death,  and the last visit if subject drops off 
from study  prematurel y, for the calculation allthe subjects will be considered to have an 
event -stop of study )will b e provided, b y treatment group and overall. 
The number of patients who prematurely  discontinue study  participation or intake of study  
medication will be summarized with respect to the key  subgroups , see section 6.4.1 .andthe 
reasons for premature discontinuation of study  and / or study  treatment. If the proportion of 
patients who withdraw across the dose groups is not fairly  balanced, the impact on the 
primary  variables will be further explored. To further explore the missingness pattern with 
regards to the “missing at random” assumption, the mean of the baseline values of the efficacy  
variable will be summarized for patients with and without post -baseline observat ions, by  
treatment group and overall. 
For the anal ysis of the primary  and secondary  variables, it cannot necessarily  be assumed that 
data are missing at random. As the choice of primary  anal ysis will be based on assumptions 
that cannot be verified, the ro bustness of the results of the primary  analy sis will be 
investigated through appropriate sensitivity  analy ses making different assumptions, in 
accordance with the EMA “Guideline on missing data in confirmatory  clinical trials”. Detail 
missing data handlin g are specified in Section 6.2.1.4 .
When appropriate, the following rules will be implemented so as not to exclude subjects from 
statistical analy ses due to missing or incomplete data:
Date of CHF diagnosis 
For cases where st art month and year are reported but day  is missing, impute it with 
the 1stday of month. If the m onth is not available, this date will not be imputed. 
Clinical outcomes
For cases where start month and y ear are reported but day  is missing, impute the 
maximum of (date of randomization, first date of study  medication, 15.month.y ear). 
For cases where onl y start year is reported or completely missing ,impute the 
maximum of (date of randomization, first date of study  medication, 15 .01.y ear), but 
not later than death date if the subject died. 
Heart failure related c oncomitant medication start date
For case where start month and y ear are reported but day  is missing, impute it with 
15thday of month. For cases where only  start y ear is reported or completel y missing, 
impute it asmaximum of (15.01.year, randomization).
Heart failure related c oncomitant medication stop date
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 11 of 39:
For case where stop month and y ear are reported but day is missing , impute it as 
minimum of  [(15, month, year) and (last visit date) and (death date)] .
If the stop day  and month are missing , then the stop date will be imputed as minimum 
of [(15.12.y ear) and (last visit date) and (death date)].
If the date is completely missing then the stop date will be imputed as minimum of 
[the last visit date and death date]. If the concomitant medication is “Ongoing at 
subject's last visit”, for the respective stop date variable the ‘last visit date’ from the 
corresponding domain is merged in the concomitant medication database by data 
management programming.
Study medication start date for subjects took study medication
If the start date and time is missing it will be imputed with the randomization date and 
time. I f start date and t ime is recorded as earlier than randomization and cannot be 
clarified, date and time of randomization will be used for the statistical analysis.
Study medication stop date for subjects took study medication
If the stop day  is missing, but the stop month and stop y ear are available then the stop 
date will be imputed as minimum of [(15, month, y ear) and (last on treatment visit 
date before the observational visit) and (death date)].
If the stop day  and month ar e missing or the date is completely  missing then the stop 
date will be imputed as minimum of [the last on treatment visit date before the 
observational visit and death date].
4.4 Interim Analyses and Data Monitoring
A formal interim anal ysis is not planned. Pe riodic data review b y a DMC will be performed to 
monitor safety  and tolerability . An Independent Data Monitoring Committee (IDMC) will be 
applied to this study .An external statistical analy sis center will provide results to the DMC
4.5 Data Rules
Generally , for each date stored in database a set of organizational variables will be derived in 
order to describe the temporal context of that date in the specific stud y: Phase of treatment 
(pre, during or post study treatment), day relative to the start of study tre atment, day  relative 
to the end of study  treatment will be provided .
4.5.1 Baseline and Change from Baseline
For efficacy  endpoints, the efficacy  baseline is defined as the last available value prior to or 
on the date of randomization. Safety  baseline is defined as the last available value before the 
first study  medication administration . If values are missing at the baseline (visit 2, week 0), 
data recorded at run-in (Visit 1) will be considered as safety  baseline value. If run-inrecor d is 
also missing, the baseline value will be left as missing.
Change from baseline for vital signs or laboratory  parameters will in general be display ed as 
the difference to baseline defined as:
Change = Post baseline value –baseline value .
In addition, for some parameters the relative change will be anal yzed defined as
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 12 of 39:
Relative change = 100 %* [(post baseline value –baseline value) / baseline value ].
4.5.2 Repeated Measure ment s
At all visits post -randomization and if not stated otherwise, onl y the values at s cheduled time 
points will be used for analy sis, although unscheduled results will be included in tables 
reporting an y abnormalities, e.g. incidences of high laboratory  abnormalities.
For the derived visit “Any  time post baseline” this will include any  meas urement after 
initiation of study  drug, including unscheduled assessments.
4.5.3 Laboratory Data Handling
The data of hematology, clinical chemistry , and coagulation will be provided by central 
laboratories. Additional re- tests for liver monitoring will be done locall y.
For values which are below the lower limit of quantification (LLOQ), half the value of the 
LLOQ will be used for analy sis.  Differences between two values of below the LLOQ will be 
assigned values of 0. 
In case of measurements above the upper limit of quantification (ULOQ), the following rules 
will be applied:
The ULOQ will be used for calculations.
Corresponding tables and figures will get a footnote indicating that “Values above the 
upper limit of quantification of ULOQ were replaced b y ULOQ.”
Tables display ing maximum values will show up “>ULOQ” as maximum.
If more than one assessment occurred at an y post -baseline visit (repeated measures at same 
visit), the last valid (non-missing ) value will be used in the summaries. Unscheduled 
laboratory  data will be listed and included in the summary  tables.
4.5.4 Subgroup analyses
In order to assess the homogeneity  of the dose response across the most important prognostic 
and predictive factors, subgroup anal yses will be performed. 
‘Key ’ subgroups include : 
LVE F(%) at baseline: ≤25 vs. >25
LVEF(%) at baseline: ≤40 vs. >40 
LVEF(%) at baseline: ≤45 vs. >45
NT-proBNP (pg/ml) at baseline: ≤ median vs. > median
NYHA class at baseline: II vs. III  / IV
Prior ß- blocker: yes vs. no
All other exploratory  subgroups comprise demographic and baseline characteristics specified 
in section 6.1.2 . 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 13 of 39:
If the total number of subjects in a subgroup categor y istoo small , the respective subgroup 
category  will be either omitted from the analysis or combined with other categories, if a 
logical combination to another subgroup category  is possible.
Prior hospitalization for heart failure is defined based on one of inclusion criterion s.
CRF item (subject group) selected Prior hospitalization (outpatients 
visit)
CHF Hospitalization/ unscheduled outpatient 
clinic visit with BNP/NTproBNP measurement 
in the last 3 months Yes
Only  BNP/NTproBNP measurement in the l ast 
4 weeks No
Combination of CHF Hospitalization/
unscheduled outpatient clinic visit with
BNP/NTproBNP measurement in the
last 3 months and additional measurement in 
the last 4 weeksYes
4.6 Blind Review
The results of the final data assessment will be documented in the final list of important 
deviations, validity  findings and assignment to analy sis set(s). Any changes to the statistical 
analysis prompted by  the results of the review of study  data will be documented in an 
amendment and, if applicable, in a supplement to this SAP.
5. Analysis Sets
Documentation of protocol deviations and assignment of patients to anal ysis sets will be 
performed according to the sponsor’s applicable Standard Operating Procedures and  ocor 
Operation Instructions.
5.1 Assignment of a nalysis sets
Final decisions regarding the assignment of subjects to analysis sets will be made during the 
review of stud y data and documented in the final list of important deviations, validity  findings 
and assignment to anal ysis set(s) (see section 4.6).
Data for all patients who signed informed consent but were not randomized will not be 
included in an y statistical anal yses except standard disposit ion tables and listings provided in 
the clinical study  report (Screening failures and discontinued patients). 
The statistical anal ysis sets are defined as follows:
Full analysis set (FAS)
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 14 of 39:
The FAS population consists of all randomized unique patients. According to the ICH E9 
guideline, this anal ysis set is as complete as possible and as close as possible to the intent -to-
treat (ITT) ideal. Patients will be anal yzed as randomized. The FAS will be used to display  
baseline characteristics and to display  efficacy  analy ses.Sensitivity  anal yses are based on the 
FAS population .For the anal yses conducted in FAS, patients will be analyzed as randomized 
per IxRs. 
Safety analysis set (SAF)
The SAF population consists of all randomized patients who received at le ast one dose of 
study  medication after randomization. The SAF will be used to display  safety  analy ses. For 
analyses conducted in SAF , patients will be analy zed as treated.
Per-protocol set (PPS)
The protocol defines a PPS. Since there are two primary  efficacy variables, we will define 
PPS L VEF and PPS BNP , specific to the presence of non- missing da ta for each variable 
separately .
Per-protocol set for LVEF (PPS LVEF):  The PPS LVEF population consists of all FAS 
population patients without validity  findings. Validity  findings may  include adherence and 
compliance issues and the violation of inclusion  / exclusion criteria affecting efficacy  
evaluation. If the left ventricular ejection fraction of this subject is measured after first dose of 
study  medication but within a specified time frame this subject will not be excluded from PPS
LVEF .The patients with invalid/missing baseline value or missing post -baseline value not 
due to CV deat h or HF hospitalization will be excluded from the PPS L VEF .The primary  
analysis of LVEF will be conducted in PPS L VEF.
Per-Protocol set for NT -proBNP (PPS BNP): The PPS BNP population consists of all FAS 
population patients without validity findings. Vali dity findings may  include adherence and 
compliance issues and the violation of inclusion  / exclusion criteria affecting efficacy  
evaluation. If the NT-proBNP (pg/mL)   of this subject is measured after first dose of study  
medication but within a specified t ime frame this subject will not be excluded from PPS BNP. 
The patients with invalid/missing baseline value or missing post -baseline value not due to CV 
death or HF hospitalization will be excluded from the PPS BNP. The primary anal ysis of NT -
proBNP will be conducted in PPS BNP.
A list of potential validity findings will be provided in a separate important deviations and 
validity  specifications document which will be finalized before database lock. The detailed 
definitions and the assignment of patients to this analy sis set will be based on the validity  
review meeting. Patients will be anal yzed as treated.
Pharmacokinetic analysis set (PKS)
The PKS population consists of all patients treated with neladenoson bialanate with at least 
1valid BAY 84-3174 plasm a concentration and without protocol deviation that would 
interfere with the evaluation of the PK data.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 15 of 39:
6. Statistical Methodology
The formal statistical analy ses will be both descriptive and inferential. Summaries will be 
provided for each of the treatment g roup. All of analy ses planned in this SAP will be repeated 
in Japanese subjects only.
6.1 Population characteristics
6.1.1 Disposition of Subjects
The following will be tabulated overall and/or by  treatment group:
Study  sample sizes (FAS , PPS LVE F, PPS BNP, SAF and PKS )
Study  sample sizes by  region, country , and site
Subject disposition
Number of subjects and primary  reasons for screening failures (onl y overall)
Number of subjects and primary  reasons for permanent discon tinuation of study  
medication (b y treatment group and overall for FAS and SAF)
Number of subjects and primary  reasons for discontinuation from study  (by treatment
group and overall for FAS and SAF)
6.1.2 Demographic and Baseline Characteristics
Descriptive summaries of demographics and baseline characteristics will be presented b y 
treatment group and overall for the PPS LVE F, PPS BNP ,FAS and SAF populations. 
Comparability  of the treatment groups with respect to demographics and baseline 
characteristics will be assessed using the descriptive summaries. Same analy ses will also be 
performed for subjects who prematurel y discontinue study  participation or intake of study  
medication .
The following demographic data will be summarized:
Age at baseline (years);
Age category : <65, 65 -75, >75 years;
Gender (male vs. female)
Race and ethnic ity;
Height (cm);
Weight (kg) at baseline;
BMI (kg/m² );
BMI category : ≤30 vs. >30 kg/m² ;
Tobacco smoking history
Alcohol consumption history
Recent caffeine -containing beverage and chocolate consumption history
The following baseline characteristics will be summarized:
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 16 of 39:
LVEF(%) at baseline: ≤25 vs. >25
LVEF(%) at baseline: ≤40 vs. >40 
LVEF(%) at baseline: ≤45 vs. >45
LVEF(%) at baseline: ≤mean vs. >mean
NT-proBNP (pg/ml) at baseline: ≤ median vs. > median
NYHA class at baseline: II vs. III  / IV
Prior ß-bl ocker: yes vs. no
Region: North America /West Europe / East Europe / Asia
Region: Japan vs. rest -of-the-world (anal ysis to be included in reports specific for 
Japan only )
Time of CHF diagnosis to randomization (months): ≤3 vs. >3
Prior hospitalization for heart failure: yes vs. no
Etiology  of CHF: ischemic vs. non -ischemic
Diabetes: yes vs. no
Atrial fibrillation: y es vs. no
Hypertension: y es vs. no
Prior CHF medication:
oPrior ß- blocker in max tolerated dose: yes vs. no
oPrior use of ivabradine: yes vs. no
oPrior use of MRA : yes vs. no
oPrior use of ACE inhibitor: y es vs. no
oPrior use of ARB: yes vs. no
oPrior use of angiotensin receptor -nepril ysin inhibitor (ARNI): y es vs. no
Estimated GFR (ml/min/1.73 m2): ≤60 vs. >60
6.1.3 Medical history
Medical history  findings will be summarized using medical dictionary  for regulatory  activities 
(MedDRA ,version refer sto TS domain ) terms for the FAS population by  treatment group. 
6.1.4 Prior and Concomitant Medications
All non -study  medications taken during the study  will be coded u sing the World Health 
Organizati on Drug Dictionary  (WHO -DD) in its latest version which is specified in the TS 
domain and the Anatomical Therapeutic Chemical (ATC) classification s ystem. Coding will 
include the drug class and preferred drug name.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 17 of 39:
Non-study medications taken during the study  will be categorized as prior medications, 
concomitant medications during the treatment period, and post treatment medications during 
the safet yfollow -up.
Prior medications will be defined as a non -study  medication with a stop date prior to the first 
dose of study  treatment.
Concomitant medications will be defined as:
Non -study  medications with a start or stop date on or after the date of the first dose 
of study  treatment;
Non -study  medications that started prior to the first dose of study treatment and are 
ongoing during the treatment period;
Non -study  medications with partial start dates that indicate that the medication could 
be concomitant in relation to the date of the first dose of study treatment;
Non -study medications with completely  missing start dates, unless their stop dates 
confirm otherwise (i.e. the stop date is before the first dose of study treatment).
Post treatment medications are defined as non -study  medications taken up to 6 weeks after the
laststudy  medication intake .
All concomitant medications will be listed, including verbatim descriptions and coded terms, 
and flags for prior medications. Prior, concomitant, and post treatment medications will be 
summarized using frequencies of subjects repo rting each drug category  and perferred drug 
name. Additionally  
concomitant medications of interest required bythe HF guideline, i.e. 
ACEI /ARB/ARNI, MRA, beta blockers and/or Ivabradine and their combination s
other medications of interest relevant to the cardiovascular s ystem, i.e. digitalis 
glycosides,loop and thiazide diuretics, Potassium sparing agents (excluding MRAs), 
Statins, anticoagulants, antiplatelets , natriuretic peptides,  soluble guan ylate cy clase 
stimulators, GLP-1 antagonists, insulins,  and SGLT -2 inhibitors , 
will be summarized using frequencies of subjects reporting each preferred drug name at 
baseline and post -baseline .Frequency  of subjects who experienced dose increase, dose 
decrease or no dose change of concomitant medication of interestedrequired in the HF 
guideline will also be summarized. 
For each subject, multiple records of the same concomitant medication will be counted once 
within a drug class and preferred name.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 18 of 39:
6.2 Efficacy
6.2.1 Primary efficacy variables and analyses
6.2.1.1 Primary efficacy variables
Absolute change from baseline in left ventricular ejection fraction (LVEF; %) after 20 
weeks measured b y echocardiograph y, i.e., LVEF at week 20 minus LVEF at baseline .
Absolute change from baseline in log- transformed NT -proBNP (pg/mL) after 20 
weeks, i.e., log -transformed NT -proBNP at week 20 minus log -transformed NT -
proBNP at baseline. 
6.2.1.2 Primary analysis of primary efficacy variables
Primary  anal ysis will be performed in PPS L VEF and PPS BNP respectively, a subset of the 
FAS comprising “compliant and adherent” patients (as much as possible, defined via validit y 
criteria). To avoid bias, the PPS LVEF and PPS BNP will also include those “compliant and 
adherent” patients who are “censored” due to CV death or a hospitalization for HF preventing 
the as sessment of the relevant efficacy  endpoints 20 weeks after randomization to take place 
as planned. For missing post- baseline value due to CV death or stud y drug/study  
discontinuation due to HF, a worst case approach (WOV) will be applied. The worst change 
by treatment group will be calculated.  I f the worst change in that treatment group is positive 
for LVEF / negative for NT- proBNP , the worst case in that treatment group is 0. The missing 
change from baseline value will be imputed with a multiple 1.0 of the median of worst 
change s from baseline value among all treatment group s.The post -baseline value at week 20 
will be calculated accordingl y as baseline value + imputed change from baseline. If this 
imputed  post -baseline value for LVEF is < 0% in case of CV death preventing the 
measurement, then the post -baseline value will be replaced with 0 and the imputed change 
from baseline will be modified to (- baseline value). Similarly , if the imputed post -baseline 
value is < 5% in case of a hospitalization for HF and no CV death preventing the 
measurement, the post -baseline value will be set to 5% and the corresponding imputed change 
from baseline will be reset to (5 -baseline value).
For both primary  efficacy  variables, i t is planned to perform a test for a dose -response signal,
respectivel y, under the assumption of a nearl y monotone dose -response relationship in the 
dose range considered. The MCP -Mod method (5)combining multiple comparison 
procedures (MCP) principles with modeling techniques will be used for the primary  statistical 
analysis of the primary  efficacy  variable s. This method allows the flexibility  of modeling for 
dose estimation, while preserving the robustnes s to model misspecification associated with 
MCP procedures. The MCP -Mod method will be used based on SAS programs provided ( 9) 
and the results may  be validated within R ( 10) with the actual DoseFinding package ( 11).
Two primary  variables have been defined to better evaluate multiple dimensions of the 
treatment effect, thereb y adding a source of multiplicity. The overall outcome of the primary  
efficacy  analysis will be considered positive if at least one of the two null hy potheses related 
to the primary  efficacy  variables can be rejected. The Hochberg (step -up) procedure will be 
applied to control the family -wise error rate (FWER):
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 19 of 39:
Consider the null hy potheses for LVEF, H 0,LVEF, and for NT -proBNP, H 0,NT -proBNP , and their 
associated raw p -values p LVE Fand p NT-proBNP .  The Hochberg test is performed using the 
following steps:
1.If max(p LVE F, pNT-proBNP ) ≤α = 0.05, both null hy potheses H 0,LVEF and H 0,NT -proBNP will 
be rejected and the procedure stops. 
2.If max(p LVE F, pNT-proBNP ) > α = 0.05 and min(p LVE F, pNT-proBNP ) ≤α/2 = 0.025,
we will fail to reject the null hy pothesis related to the larger p -value max(p LVEF, pNT-
proBNP ) and the null hy pothesis re lated to the smaller p -value min(p LVE F, pNT-proBNP ) will 
be rejected. 
3.Otherwise, we will fail to reject both null hy potheses H0,LVEF   and H0,NT -proBNP .
Assumptions
Five active doses of neladenoson bialanate will be used in this study : 5 mg, 10 mg, 20 mg, 30 
mg, and 40 mg, as well as a placebo arm corresponding to a 0 mg dose. 
The measurements of the primary  efficacy  variable sare assumed to be normally  distributed 
with the same standard deviation σ and indep endent between patients , respectivel y.
LVEF : The following assumptions were made for the absolute change from baseline in LVEF 
over 20 weeks:
the expected mean effect under the placebo dose is conservativel y assumed as an 
absolute increase from baseline of up to = 2% with a standard deviation of = 7%
while the maximum observable mean effect under neladenoson bialanate within the 
dose range considered is assumed as an absolute increase of = 5% with a standard 
deviation of = 7% .
This results in an ex pected maximum effect size of (5 -2)/7 = 3/7 = 0.43 under conservative 
assumptions. Note that the threshold of clinical relevance is an absolute difference of 3% in 
the change from baseline over the placebo control group.
NT-proBNP: The following assumption s were made for the absolute change from baseline in 
the log- transformed NT -proBNP over 20 weeks:
the expected mean effect under the placebo dose is assumed as an absolute decrease 
from baseline of -0.105 log(pg/mL) with a standard deviation of = 0.85 lo g(pg/mL), 
which is equivalent to a 10% relative reduction from a mean of 2,500 pg/mL  at 
baseline.
while the maximum observable mean effect under neladenoson bialanate within the 
dose range considered is assumed as an absolute decrease from baseline of 
-0.357 log(pg/mL) with a standard deviation of = 0.85 log(pg/mL ), which is 
equivalent to a 30% relative reduction from a mean of 2,500 pg/mL at baseline.
It is assumed that the respective primary  response efficacy  variable, denoted as  , is observed 
for the 6 parallel groups corresponding to doses levels: (placebo =)  1<  2< … <  k, where 
k= 6.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 20 of 39:
For patient jwithin treatment group ithe response can then be described by  the following 
model:
   =  ( , )+    ,					   	~ (0,  ),					 = 1,…, ,		  = 1,	…,	   ,	
where  (.)is parameterized by  a vector of parameters  and    is the error term.
A candidate set with M=5 different dose response shapes  (.)based on four models was 
chosen for the MCP- Mod method. Table 6–1display s the response expressions for the shapes 
in the candidate set s for both, change in LVEF and change in log -transformed NT -proBNP . 
Figure 6–1shows the corresponding dose -response shapes for change in LVEF . The model 
parameters were obtained through discussions with experts in the clinical team, taking prior 
beliefs and uncertaint y into account. The dose -response shapes for NT -proBNP are equivalent 
to those for LVEF but with decreasing trends. 
Table 6–1: Dose -response shapes used in the candidate set
Model Response as function of dose d
LVEF NT-proBNP
Linear 2 + 0.075 d –0.105 – 0.0063 d
Sigm oidal E max1 2+ 3.007689 d4/ (94+ d4) –0.105 – 0.2526 d4/ (94+ d4)
Sigm oidal E max2 2 + 3.375d3/ (203+ d3) –0.105 – 0.2835 d3/ (203+ d3)
Emax 2 + 3.09375 d / (1.25 + d) –0.105 – 0.2599 d / (1.25 + d)
Quadratic 2 + 0.2 d – 0.00333 d² –0.105 – 0.0168 d + 0.00028 d²
Figure 6–1: Dose -response shapes used in the candidate set for change in LVEF

Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 21 of 39:
Based on the standardized versions of the models in the candidate set and the sample size 
allocation planned for this study , the optimum contrast coefficients for the 5 contrast tests on 
the dose -response shapes can be derived for both primary  variables ( Table 6–2). 
These contrast coefficients will be updated based on the actual number of subjects per 
treatment group which are finally  available for the anal ysis.
Table 6–2: Contrast coefficients
Model Contrast coefficients for dose
0.0 5.0 10.0 20.00 30.00 40.00
Linear -0.674 -0.159 -0.186 0.077 0.340 0.603
Sigm oidal E max1 -0.784 -0.223 0.004 0.315 0.342 0.347
Sigm oidal E max2 -0.615 -0.197 -0.290 0.130 0.423 0.550
Emax -0.901 0.046 0.170 0.215 0.231 0.240
Quadratic -0.815 -0.129 -0.024 0.288 0.392 0.288
Analysis
Step 1: Detection of dose -response signal
For detecting an overall trend, or a dose -response signal, each of the M=5 dose -response 
shapes in the candidate set will be tested, using a single contrast test based on the updated 
version of contrast coefficients taking the actual sample sizes per treatment group into 
account.
For each model m, m = 1, …, 5, in the candidat e set 
the null hy pothesis    :     = 0
will be tested against 
the respective 1 -sided alternative h ypothesis    :     > 0, 
where    =(    ,…,    ) = (   (  ,   ),…,   (  ,   ))′and
  	isthe standardized version of the dose- response model  ( , )=	  +    ( ,  ). In 
this parameterization,   is a location parameter and   is a scale parameter such that only  
  	determines the shape of the model function. 
The contrast coefficients cm1… c mifor the m -th model are chosen such that they  maximize the 
power to detect the underly ing model. These optimal contrast coefficients depend onl y on the 
parameters in the standardized model function   , which determine the model shape ( 5) and 
the actual group sample sizes (which is known after unblinding of the stud y). The ith member 
of the optimal contrast vector copt,mfor testing the shape m odel mis proportional to
  (    ,…, ̅),  = 1,…,6,   
where  ̅ =    ∑       
    . In case of unequal sample sizes per treatment arm, copt,mcannot 
be expressed in closed form and numerical optimization techniques are required ( 9, 11 ). The 
copt,mis derived by fulfilling the condition ∑    = 1 
    .
The single contrast test for detecting the m -th model shape is defined by
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 22 of 39:
  =∑    
      
 	 ∑    /   
   ,  = 1,…,5,      where     =∑ ∑              
    
   
   .
Under the null h ypothesis of no dose -response effect, i.e.    = ⋯ =	    , the test statistic 
  = (   ,…,  )′follows a central multivariate t distribution with N-6degrees of freedom and 
correlation matrix    = (    ), where      =	∑      /   
   
 ∑    /   
   ∑    /   
   	.
The final test statistic     is based on the maximum contrast test and a “proof-of- concept” 
dose-response relationship is detected if this maximum statistic      , and thus at least 
onesingle contrast test, is statistically  significant, while controlling the family wise error rate 
at level .  If     denotes the multiplicity  adjusted critical value, a dose -response s ignal is 
established if      	≥     .The smallest of the corresponding adjusted p -values will be used 
for the Hochberg test.
This analy sis will be performed for the FAS and PPS LVEF, PPS BNP populations
respectivel y, where the PPS LVEF and PPS BNP analysis is the primary  analy sis. 
If no candidate model is statistically  significant, the procedure stops, indicating that a dose-
response relationship cannot be established from the observed data.
Out of the statistically  significant models in the candidate set a best model can be selected for 
the next step: modeling and estimation. 
Step 2: Modeling and estimation of target doses
If a dose -response signal is established, the selected dose- response model(s) will be fitted to 
the observed data to estimate the model parameters. 
The estimated dose- response model will be plotted against the doses including 90% 
confidence bands. Once the dose-response model has been successfull y fitted to the data, 
target dose(s) of interest are estimated. Given a clinically  relevant effect ∆f, a minimum 
effective dose (    ∆) associated with model  ( , )is defined as
   ∆=argmin ∈(  ,  ]{ ( , )	≥  (  , )+	∆}.
Estimates of    ∆will be calculated for a clinically  relevant change in LVEF assumed as 
∆wil% and potentially  a plausible range of ∆values which will be defined based on the 
observed data. Estimation for change in log -transformed NT-proBNP will be performed 
analogously , ensuring an adequate back-transformation to allow for better interpretabili ty of 
the results . In addition, estimates considering confidence bounds for the predicted value at a 
certain dose may  be used. The final choice of the target dose depends on the evaluation of the 
primary  efficacy  variable sand other efficacy  variables, as well as safet y considerations.
Additionally  LVEF and increasing change from baseline, NT-pro-BNP and decreasing change 
from baseline, and log -transformed NT -proBNP and decreasing change from baseline will be
descriptivel y summarized by treatment and overall, and visit in PPS LVEF and PPS BNP 
respectivel y.
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 23 of 39:
6.2.1.3 Secondary analysis of primary efficacy variables
As a secondary  anal ysis pairwise comparisons of the active neladenoson bialanate dose 
groups with the placebo group will be performed without control ling the family -wise error 
rate, b y calculating the 90% confidence interval for the difference in primary  efficacy  variable 
between each active dose of neladenoson bialanate and placebo.
6.2.1.4 Sensitivity analyses of primary efficacy variables
6.2.1.4.1 Sensitivity anal ysis of primary efficacy variables in PPS LVEF and PPS 
BNP
As a sensitivity  anal ysis, primary  anal ysis of primary  efficacy  variables on the “completers 
and treatment adherers” excluding the censored patients in the per -protocol analy sis set will 
be repeate d. This strategy  leads to unbiased estimates only  if missing values are “missing 
completely  at random” (MCAR), i.e. the missingness – including missing data due to death –
is independent of both observed and unobserved outcomes. This condition is unlikely  to hold 
exactly  but rather approximately .
Further sensitivity  anal yses on the PPS LVEF and PPS BNP may be performed if the missing 
data patterns suggest further exploration.
6.2.1.4.2 Sensitivity analysis of primary efficacy variables in FAS
Additional e fficacy  anal yses in the FAS will include the following:
Primary  anal yses of primary  efficacy  variable s specified in section 6.2.1.2 willbe
performed in FAS without any  imputa tion. 
Generally , it will be assumed that missing observations for the respective efficacy  
variables are missing at random. This implies that the behavior of the post dropout 
observations can be predicted from the observed variables using appropriate 
imput ation models. L ikely  exceptions to the missing at random assumption are 
observations which are missing due to a patient’s CV death or HF hospitalization prior 
to the visit in Week 20. These observations can be assumed to be missing not at 
random (MNAR), i. e., that missingness depends both on observed and unobserved 
outcomes and that an explicit model for the patient’s statistical behavior after drop -out 
(or death) is required. Therefore, an anal ysis based on a pattern mixture framework ( 6) 
with different imputation rules depending on the reason for missingness will be used 
using a multiple imputation model, followed by a modification of the imputed data 
apply ing penalties: 
1.First, multiple imputation will be applied to draw sets of completed data, using an 
appropriate imputation model. Baseline characteristics which should be considered 
in the imputation model include but are not restricted to the baseline values of the 
respe ctive efficacy  variable, the treatment group, and sex. 
2.The imputed data will be modified by  appl ying penalties. The penalt y is chosen as 
the median of the worst changes from baseline across treatment groups (or 0 if the 
median worst change should be posit ive for LVEF or negative for 
LVESV/LVEDV or log- transformed NT -proBNP/hs -TNT).
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 24 of 39:
3.After modify ing the completed data sets, the primary  anal ysis specified in section 
6.2.1.2 will be applied to the multipl eimputed datasets and the point estimate and 
variance of the contrast from multipl eimputed datasets willbe combined based on 
Rubin’s rule (8).For more details seeAppendix 9.4.
Primary analyses where for each patient without an observation at the visit in Week 20 
the missing value will be imputed according to a last observation carried forward 
approach, including the baseline value. 
For reproducibility , the SAS seed number for creating the ran dom numbers for the multiple 
imputation will be set to the study  number . 
6.2.1.5 Additional analysis of primary efficacy variables
Adjusted primary  anal ysis of primary  efficacy  variables specified in section 6.2.1.2 (dose -
response test) will performed in PPS LVE F and PPS BNP respectivel y. Baseline values of 
atrial fibrillation , eGFR (≤60 mL/min/1.73m2, >60 mL/min/1.73m2), gender , age group
(<50, 50- 75 and >75), and BMI > 3 0kg/m2 will be used as covariates. In exploratory  manner, 
the absolute change in LVEF (%) from baseline to week 20 will be categorized into four 
groups ( ≤ -5, > -5 to <5, 5 to <10, ≥10). The number (%) of patients in each category  of 
LVEF will be display ed by  treatment group and overall. For further details including further 
categorization see the TLF Specification document.
6.2.2 Secondary efficacy variables and analyses
6.2.2.1 Secondary efficacy variables
Secondary  efficacy  variables across different domains are: 
Key echocardiographic parameters, measured values and absolute change from 
baseline at 20 weeks:
oLeft ventricular end -systolic volume (LVESV; mL) 
oLeft ventricular end -diastolic volume (LVEDV; mL)
High sensitivity  troponin T (hs-TNT; ng/L), measured values (log transformed) and 
absolute  / relative change from baseline at 20 weeks as a biomarker of m yocardial 
injury
Time from randomization to clinical outcomes: CV mortality , HF hospitalization and 
urgent visits for HF (separat e and composite)
6.2.2.2 Primary analyses of secondary efficacy variables
The primary  anal ysis of key echocardiographic parameters will be performed in PPS L VEF 
and other secondary  efficacy  variables will be performed in PPS BNP . The missing values of 
post baseline of LVESV and LVEDV will be imputed by  WOV if the baseline values are not 
missing and the subjects have CV death or HF hospitalization , otherwise remains missing.  
Similarly  The missing values of post baseline of hs -TNT will be imputed by WOV if th e 
baseline values are not missing and the subjects have CV death or HF hospitalization , 
otherwise remains missing. The secondary  efficacy  variables, except for the clinical 
outcomes, will be anal yzed using similar statistical methods as for the primary  efficacy  
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 25 of 39:
variables, i.e. the MCP -Mod method with the same standardized candidate dose -response 
shapes (with the proper direction: decreasing trend for change of LVE SV,  LVEDV andlog-
transformed hs-TNT ) and corresponding coefficients as for the primary  variab les. 
Time to adjudicated clinical outcome event since randomization (using both separate and 
composite outcomes) will be described b y means of Kaplan -Meier (KM) estimates by 
treatment group . The subjects who do not have the corresponding clinical outcomes until 
week 26visit (upper time limit, i.e. 1 82+7day s) will be considered as right- censored at the 
minimum of date of last visit, date of week 26 visit, study  day 189, and date of death (in case 
death is no n CV death ).KM estimates for each visit will be tabulated .
Additionally  time to adjudicated on-treatment clinical outcome events since randomization 
(using both separate and composite outcomes) will also desc ribed up to 6 weeks after last 
dose in each treatment arm respectivel y. The subjects who do not have the corresponding 
clinical outcomes until 6 weeks after last dose will be considered right censored at minimum 
of 6 weeks after last dose , date of last visit and date of death (in case death is non CV death).  
6.2.2.3 Sensitivity analyses of secondary effic acy variables
Sensitivity  analy sesof secondary  variables except for clinical event swillbe performed in the 
FAS using the same methods as for the primary  efficacy  variable s. If the baseline values of 
secondary endpoints are missing, then only  multiple imputation will be applied for those 
subjects. Please see the details in section 6.2.1.4 .In addition clinical event swill be analy zed 
by using life table statisti cs and Kaplan -Meier estimates in FAS (only time scope up to week 
26)and SAF .
6.2.2.4 Additional analyses of secondary efficacy variables
Percentage change in hs-TNT from baseline to week 20 will be summarized by  treatment 
group and overall in PPS BNP. In addition to analy ses comparing population means in the 
different dose groups, the number of patients in whom the individual change from baseline 
value crossed clinicall y meanin gful thresholds will be reported in post- hoc anal ysis 
separately .
6.2.3 Exploratory efficacy variables and analyses
Exploratory  efficacy  variables include:
Activity  (duration, intensity ) reported values and absolute change from baseline at 20 
weeks . Variables as specified in appendices 9.1
Echocardiographic parameters, as described in Section 9.4.1 of Clinical Study  
Protocol , measured values and absolute / relative change from baseline at 20 weeks
Left ventricular ejection fraction (LVEF; %), measured values, number of patients in 
whom absolute change from baseline after 20 weeks is > 5%
Mandatory  biomarkers, measured values and absolute  / relative change from baseline 
at 20 weeks, including 
oNT-proBNP (pg/mL), measured values and relative change from b aseline at 20 
weeks to assess elevated filling pressures
oUACR, cy statin -C, NGAL for the evaluation of kidney function 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 26 of 39:
KCCQ and EQ -5D- 5L, as described in Section 9.4.4.1 and 9.4.4.2 of Clinical Study  
Protocol .Frequencies of answers to individual questions will be display ed by  
treatment group and overall by  visit. In addition, changes from baseline for the single 
questions will be categorized into the categories improvement / no change / 
worsening. Frequencies of the different categories will be display ed by treatment 
group and overall by  visit.
The 7 individual domain scores and 3 summary  scores of the KCCQ and their changes 
to baseline will be summarized by  treatment group and overall by  visit as continuous 
variables. The s ymptom stability  domain (a measu re of change in s ymptoms over the 
previous two weeks) and self- efficacy  domain (a measure of patient knowledge how to 
prevent heart failure exacerbations and management of complications when they  
arise), will be reported and summarized but will not be cons idered me asures of 
treatment efficiency . Change from baseline to week 20 of KCCQ domains of Phy sical 
Limitation Score, S ymptom Frequency  Score, Symptom Burden Score, Total 
Symptom Score, Clinical Summary Score and Overall Summary  Score will be 
categorized into groups by  5 points and the number (%) of patients in each category  of 
KCCQ domains respectively  will be display ed by treatment group and overall. For 
scoring see Appendix, Section 9.3. The EQ visual analogue scale (VAS) values of the 
EQ-5D- 5L and their changes to baseline will be summarized by  treatment group and 
overall by visit as continuous variable.
Time from randomization to a ll-cause mortal ity, non -fatal m yocardial infarction, non -
fatal stroke
Change in NYHA class
Time to adjudicated clinical outcome events since randomization (using both separate and 
composite outcomes) will be described by means of life table statistics and Kaplan -Meier 
estimates in FAS. Other than time to event variables will be analy zed descriptivel y in FAS
without missing data. In addition, percentage change in NT -proBNP from baseline to week 20 
will be summarized by treatment group and overall. The percentage change of NT-proBNP 
from baseline to week 20 will be categorized into four groups (≤ -20, > -20 to ≤+20, >20 and 
≤+30, > +30) . The number (%) of patients in each category  of NT-proBNP respectivel y will 
be display ed by  treatment group and overall. 
6.3 Safety
The summa ries of the safety  data will be completed for the safet y analysis population (SAF). 
No formal statistical test will be performed for the safet y variables .
6.3.1 Extent of exposure
Study  medication will be summarized for the safety  popul ation by treatment group, using 
descriptive statistics such as frequency  and proportion (for categorical variables), mean, 
median , and standard deviation (for continuous variables).
All summaries related to intake of study  medication will be by  treatment group based on SAF :
The t reatment duration (date of last study  medication -date of first stud y medication+1 
day) will be summarized descriptivel y. Additionally the number of subjects by 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 27 of 39:
treatment duration category  will be given ( ≤28 days, >28-≤56 days,>56-≤84 days,
>84- ≤140 days).
The time on study  medication (treatment duration excluding day s off stud y 
medication) will be calculated and summarized descriptively .
The number of tablets taken will be summarized descriptivel y, as well as 
corresponding extent of exposure ( total a mount of intake in mg ).  
6.3.2 Treatment Compliance
Compliance is defined as 100*number of tablets taken / number of tablets planned. 
The compliance will be summarized descriptively  by treatment group and overall.  In 
addition, compliance will be categorized into three groups (<80%, 80- 120%, >120%) and 
summarized by  treatment group and overall.
6.3.3 Adverse events
All a dverse event s (AEs) will be coded according to the Medical Dictionary  for Regulatory  
Activities (MedDRA) in its latest version which is specified in the TS domain . 
A treatment -emergent AEis defined as an y event arising or worsening after the start of study  
drug administration until 6 weeks after the last study  medication intake.
Summary  statistics (frequency  and percentage of subjects) will be pres ented by  treatment 
group using MedDRA for the following:
Incidence rate of treatment -emergent AEs.
Incidence rate of drug-related treatment -emergent AEs.
Incidence rate of treatment -emergent AEs leading to death .
Incidence rate of treatment -emergent AEs leading to permanent withdrawal of 
medication. 
Incidence rate of treatment -emergent AEs leading to interruption of medication. 
Incidence rate of treatment -emergent serious adverse events.
Incidence rate of treatment- emergent drug -related serious adverse events.
Incidence rate of adverse events of special interest:
oSymptomatic brady cardia (HR < 50 bpm)
oFindings in ECG and  / or AVIVO device as follows:
Mobitz ty pe I AV -block leading to withdrawal or interruption of s tudy 
drug 
Mobitz ty pe II AV block leading to withdrawal or interruption of study  
drug or leading to an y change in therap y 
Third degree AV blocks
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 28 of 39:
Listing of treatment -emergent AEs leading to withdrawal: subject ID, investigator AE 
term, SOC, preferred ter m, start and stop date of study  drug administration, start and 
stop date (relative day s)of AE, drug related (y es/no), serious (y es/no), intensity , 
outcome.
Listing of treatment -emergent serious AEs: subject ID, investigator AE term, SOC, 
preferred term , start and stop dates of study  treatment, start and stop date of AE ,drug 
related (y es/no), outcome, action taken. 
6.3.4 Deaths
Deaths reported during the study period will be tabulated by  treatment group.
Summary  table of deaths ( all deaths, all deaths during treatment and up to 6 weeks
after last dose of study  drug, all deaths later than 6 weeks after last dose of study  
medication)
Listing of subjects who died during treatment and up to 6 weeks after last dose: 
subject ID, start and stop date of stud y medication, date of death, relative day  and 
cause of death.
6.3.5 Clinical laboratory evaluations
All laboratory  evaluations will be done by  central laboratory . 
Hematology : erythrocy tes, hemoglobin, hematocrit, MCV, MCH, MCHC, reticulocy tes, 
leukocy tes, differential blood count, platelets
Clinical chemistry : aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (AP), gamma glutamy l transpeptidase (GGT), lactate dehy drogenase 
(LDH), creatine kinase (CK), amy lase, lipase, glucose, cholesterol (HDL, LDL, total), 
triglycerides, creatinine, urea, uric acid, bilirubin, total protein, albumin, sodium, potassium, 
calcium, chloride, magnesium, anorganic phosphate 
Coagulation : partial thromboplastin time (PTT), international normalized ratio (INR)
The safet y evaluation of laboratory data will include :
Descriptive anal ysis of continuous laboratory  parameters, and their changes from 
baseline b y visit and treatment group.
Incidence rates of treatment -emergent laboratory  values outside of normal range by  
treatment group.
Listings of laboratory  data out of normal range.
Laboratory  abnormalities will be summarized in table of change from baseline by visit and 
treatment:
Change in renal function measured b y eGFR change from baseline
Change in liver function measured b y bilirubin (total and fractions), AST and AL T 
from baseline
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 29 of 39:
6.3.6 AVIVO /HealthP atch monitoring
AVIVO Mobile Patient Management S ystem is intended to continuously  measure, record and 
periodicall y trans mit ECG data. 
Notifiable ECG -findings (like AV -conduction abnormalities) triggered b y system/patients 
based, as well as reportable ECG finding according to AVIVO will be summarized in 
frequency  tables by treatment group. ECG -findings according to HealthPa tch will also be 
summarized in frequency tables by  treatment group . A table display ing the number of 
patients with AV- block > I ° according to AVIVO/HealthPatch will be provided bytreatment 
group . All patients with significant ECG -finding will be listed. The definition of the findings 
that trigger a notifiable report is in Appendices 9.1.
6.3.7 Other safety measures
The last pre -treatment safety  measurement, i.e., SBP(systolic blood pressure) , DBP (diastolic
blood pressure) , weight, body  temperature , heart rate, respiration rate and electrocardiogram 
(12 lead ECG) will be used as “baseline value.”
When more than one value is collected at the same post-baseline visit, the value retained at 
that particular visit for summary  statistics will be the average of the diff erent measures 
reported for that visit.
For each treatment group, vital signs will be tabulated and summarized b y visit for observed 
values and changes from baseline using descriptive statistics, as appropriate. 
The incidence rates of treatment -emergent 12- lead ECG abnormalities will be tabulated b y 
treatment group.  A descriptive analy sis of continuous ECG parameters and their changes 
from baseline b y visit and treatment group will also be presented.   PR interval will be 
summarized by  visit and treatment group.
6.4 Subgroup Analysis
6.4.1 Subgroups
Subgroups are specified in Section 4.5.4 .
6.4.2 Subgroup analysis of efficacy variables
Primary , secondary  and sensitivity  anal yses (without imputed values) of primary  efficacy  
variables will be performed based on key  subgroups. Additionally  primary  efficacy  variables 
will be descriptivel y summarized based on exploratory subgroups.
Secondary  efficacy  variables will be descriptivel y sum marized based on key subgroups and 
exploratory  efficacy  variables will be descriptively  summarized based on LVEF(%) at 
baseline: ≤40 vs. >40 .
6.4.3 Subgroup analysis of safety variables
Incidence rate of treatment -emergent AEs and treatment -emergent ECG abnormalities not 
presented at baseline (by AVIVO and Health Patch, Japan only )will be summarized based on 
key and exploratory  subgroups .
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 30 of 39:
6.5 Pharmacokinetics/pharmacodynamics
Pharmacokinetic anal yses will be performed on the population valid for pharmacokinet ics.
For the investigation of systemic exposure to BAY 84- 3174 and its relationship with 
treatment effects, the plasma concentrations of BAY 84 -3174 will be determined at different 
time points using a sparse sampling approach in all participating patients (see Clinical Study  
Protocol Section 9.5 ). The plasma concentration vs. time data will be evaluated descriptively  
separated b y dose and visit. Plots will be prepared pooling all individual plasma 
concentrations (naive pooling) vs. actual relative study  times (time of sample collection after 
time of study  drug administration).
Furthermore, the pharmacokinetic data and the relationship of markers of BAY 84 -3174 
exposure (e.g. C max, AUC) with treatment effects will be evaluated using non -linear mixed 
effect m odeling (NONMEM). The latter evaluation will be described in a separate anal ysis 
plan and will be reported under separate cover.
The PK bioanal ysis will be performed under the responsibility  of the Sponsor’s Bioanal ytics 
Laboratory .
6.6 Biomarker analyses
Biom arker data will be described b y the following summary statistics: arithmetic mean, 
standard deviation, median, quantiles, minimum, and maximum.
Box plotsand line plotsof mean sof biomarkers over visits ,by treatment group will be 
provided. Additional analy ses of safet y and efficacy  biomarkers and their results will be 
provided in a separate report.
7. Document history and changes in the planned statistical analysis
Version Date Action
Version 1 .0 13Nov2017
Version 2.0 19 April 2018Change the wording in section 
6.3.6
Add more detailed description of 
plots we plan to provide in section 
6.6
Version 3.0 29May 2018Add one more key  subgroup: 
LVEF(%) at baseline: ≤45 vs. >45 
Add more details of worst case 
imputation and censoring rule of 
time to event variables in section 
6.2
Some minor changes in subgroup 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 31 of 39:
analyses in section 6.4
Remove some unused variables 
from Appendix 9.1
8. References
1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD, et al. 
Confirmation of a heart failure epidemic: findings from the Resource Utilization 
Among Congestive Heart Failure (REACH) stud y. Journal of the American College of 
Cardiology . 2002;39(1):60 -9.
2.Stewart S, MacInt yre K, Hole DJ, Capewell S, McMurray  JJ. More 'malignant' than 
cancer? Five -year survival following a first admission for heart failure. European 
journal of heart failure. 2001;3(3):315 -22.
3.Executive summary : HFSA 2006 Comprehensive Heart Failure Practice Guideline. J 
Card Fail. 2006;12(1):10 -38.
4.McMurray  JJ, Packer M, Desai AS, Gong J, L efkowitz MP, Rizkala AR, et al. 
Angiotensin -neprily sin inhibition versus enalapril in heart failure. N Engl J Med. 
2014;371(11):993 -1004.
5. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling
techniques in dose- response studies. Biometrics. 2005;61(3):738 -48.
6. Carpenter JR, Kenward MG. Missing data in randomized controlled trials - a practical
guide. Chapter 6.2008.
7.Kelly  RP, Ting CT, Yang TM, Liu CP, Maughan WL , Chang MS, et al. Effective 
arterial elastance as index of arterial vascular load in humans. Circulation. 
1992;86(2):513 -21.
8.Rubin DB. Multiple imputation for nonresponse in survey s.New York: Wiley ; 1987.
9.Menon S, Zink RC . Modern Approach es to Clinical Trials Using SAS : Classical, 
Adaptive, and Bay esian Metho ds.SAS I nstitute; December 2015
10. R Core Team (2017). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL  https://www.R -
project.org/ .
11.Bjoern Bornkamp, Jose Pinheiro and Frank Bretz (2016). DoseFinding: Planning and 
Analy zing Dose Finding Experiments. R package version 0.9 -15. URL https://cran.r-
project.org/web/packages/DoseFinding
12.The Kansas City Cardiomy opath y Questionnaire Scoring Instructions (2000 -2003), 
John Spertus MD MPH [ http://cvoutco mes.org/ (6thSeptember 2013)].
13.C. Patrick G, et al. Development and Evaluation of the Kansas City Cardiomy opath y 
Questionnaire: A New Health Status Measure for Heart Failure , Journal of the 
American College of Cardiology, 2000; 35(5):1245 -55 
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 32 of 39:
14.Barnard J, Rubin DB. Small-Sample Degrees of Freedom with Multiple Imputation.
Biometrika 1999; 86: 948–955.
15.Rubin, D. B. (1996), "Multiple Imputation after 18+ Years," Journal of the American 
Statistical Association , 91, 473–489.
9. Appendices
9.1 AVIVO device v ariable specification
In the following, we describe the variables which will be anal yzed 
Activity
Variable Summary 
measure(s)Unit Length of 
interval s
activity  duration duration seconds daily
activity  intensity mean mG 1 hour
activity  intensity mean, max % daily
Notifiable findings
These should be the findings that trigger a notifiable report, definitions as below: 
Finding Notification criteria
Ventricular fibrillation alway s notified
ICD discharge alway s notified
Ventricular Tach ycardia any rate and ≥10 beats
Wide complex Tachy cardia any rate and ≥10 beats
PVCs never notified
Sinus Brad ycardia ≤30bpm
Sinus Tachy cardia ≥ 180bpm
Supraventricular tach ycardia ≥ 150 bpm AND ≥ 30 sec
A. Fibrillation or A. flutter ≥ 150 bpm AND ≥ 30 sec
A. Fibrillation or A. flutter ≤30bpm and ≥ 30 sec
A. Fibrillation or A. flutter when notification criteria are met
pause ≥ 3.0 sec
AV block 2nd (Mobitz I ) ≤ 50bpm
AV block 2nd (Mobitz II) alway s notified
Isolated 2nd degree AV block (2:1) ≤ 50bpm
High degree AV block alway s notified
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 33 of 39:
3rd Degree AV block alway s notified
other
Patient triggered Events when notification criteria are met
Technicians discretion any
9.2 Echocardiography parameters
The list of parameters is
LV ejection fraction (LVEF, %)
LV end-diastolic volume (LVEDV), LVEDV index (L VEDVI, calculated as 
LVEDV/BSA)
LV end -systolic volume (LVESV), LVESV index (LVESVI, calculated as 
LVESV/BSA)
LA size (LA diameter, area, volume index [LAVI, calculated as LAV/BSA])
Lateral e' (earl y diastolic mitral annular relaxation velocity  at the lateral mitral annulus 
by Tissue Doppler, TD)
Septal e' (earl y diastolic mitral annular relaxation velocity at septal mitral annulus by 
TD), including calculation of average e'
Global longitudinal strain (%)
Pulmonary  artery  systolic pressure (PASP), estimated by  tricuspid regurgitation 
velocity  and inferior vena cava diameter, including its change with respiration, and 
hepatic vein flow in patients with tricuspid regurgitation
Tricuspid annular plane sy stolic excu rsion (TAPSE), right ventricular (RV) s' (velocity  
of the tricuspid annular systolic excursion at the RV free wall b y TD)
Mitral regurgitation
LV mass, LV mass index (calculated as LV mass/BSA)
Wall thicknesses, incl. interventricular septum diameter (IVSD), posterior wall 
thickness (PWT), anteroseptal wall thickness (ASWT)
E, A (if in sinus rhy thm), calculation of E/A and E/e' (using lateral, septal, average e') 
ratios
E-wave deceleration time (EWDT)
Stroke volume (SV, calculated by  LVEDV -LVESV) and deri ved parameters, 
including SV index (SVI , calculated as SV/BSA), cardiac output (CO, calculated as 
SV*HR), cardiac index (CI , calculated as CO/BSA), sy stemic arterial compliance 
(SAC, calculated as SV/PP), total peripheral resistance (TPR, calculated as 
MAP /CO*80)
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 34 of 39:
Effective arterial elastance (Ea), estimated as end -systolic pressure (Pes) [Pes 
calculated as SBP times 0.9 ( 7)] divided by  SV (SBP*0.9/SV)
Final details of all echocardiography parameters to be measured and analyzed will be included 
in a separate echocardiograph y manual.
9.3 KCCQ Scoring
As described in the KCCQ Scoring instruction [ 12][13], the following derivations will be 
used.
Generally  only questions actuall y answered are used for derivation of the scores in the 
following way :
If there are nquestions in a scale, and the subject must answer mto score the scale, but the 
subject answers only  n-i, where n-i≥ m, calculate the mean of those questions as
(sum of the responses to those n-iquestions) / (n- i)
not
(sum of the responses to those n-iquestions) / n
The 7 individual domain scores and 3 summary  scores will be calculated as follows:
9.3.1 Physical Limitation
Code responses to each of Questions 1a- f as follows:
Extremely  limited = 1
Quite a bit limited = 2
Moderat ely limited = 3
Slightly  limited = 4
Not at all limited = 5
Limited for other reasons or did not do = <missing value>
If at least three of Questions 1a- f are not missing, then compute
Physical Limitation Score = 100*[(mean of Questions 1a -f actually  answer ed) –1]/4
9.3.2 Symptom Stability
Code the response to Question 2 as follows:
Much worse = 1
Slightly  worse = 2
Not changed = 3
Slightly  better = 4
Much better = 5
I’ve had no s ymptoms over the last 2 weeks = 3
If Question 2 is not missing, then compute
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 35 of 39:
Symptom Stability  Score = 100*[(Question 2) –1]/4
9.3.3 Symptom Frequency
Code responses to Questions 3, 5, 7 and 9 as follows:
Question 3
Every  morning = 1
3 or more times a week but not every  day = 2
1-2 times a week = 3
Less than once a week = 4
Never over the past 2 weeks = 5
Questions 5 and 7
All of the time = 1
Several times a day  = 2
At least once a day  = 3
3 or more times a week but not every  day = 4
1-2 times a week = 5
Less than once a week = 6
Never over the past 2 weeks = 7
Question 9
Every  night = 1
3 or more times a week but not every  day = 2
1-2 times a week = 3
Less than once a week = 4
Never over the past 2 weeks = 5
If at least two of Questions 3, 5, 7 and 9 are not missing, then compute:
S3 = [(Question 3) – 1]/4
S5 = [(Question 5) – 1]/6
S7 = [(Question 7) – 1]/6
S9 = [(Question 9) – 1]/4
Symptom Frequency  Score = 100*(mean of S3, S5, S7 and S9)
9.3.4 Symptom Burden
Code responses to each of Questions 4, 6 and 8 as follows:
Extremely  bothersome = 1
Quite a bit bothersome = 2
Moderatel y bothersome = 3
Slightly  bothersome = 4
Not at all bothersome = 5
I’ve had no swelling/fatigue/shortness of breath = 5
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 36 of 39:
If at least one of Questions 4, 6 and 8 is not missing, then compute
Symptom Burden Score = 100*[(mean of Questions 4, 6 and 8 actuall y answered) –
1]/4
9.3.5 Self- Efficacy
Code responses to Questions 10 and 11 as follows:
Question 10
Not at all sure = 1
Not very  sure = 2
Somewhat sure = 3
Mostly  sure = 4
Completely  sure = 5
Question 11
Do not understand at all = 1
Do not understand very  well = 2
Somewhat understand = 3
Mostly  understand = 4
Completely  understand = 5
If at least one of Questions 10 and 11 is not missing, then compute
Self-Efficacy  Score = 100*[(mean of Questions 10 and 11 actuall y answered) –1]/4
9.3.6 Quality of Life
Code responses to Questions 12, 13 and 14 as follows:
Question 12
It has extremely  limited my  enjo yment of life = 1
It has limited m y enjo yment of life quite a bit = 2
It has moderatel y limited my  enjo yment of life = 3
It has slightly  limited m y enjoyment of life = 4
It has not limi ted my  enjoy ment of life at all = 5
Question 13
Not at all satisfied = 1
Mostly  dissatisfied = 2
Somewhat satisfied = 3
Mostly  satisfied = 4
Completely  satisfied = 5
Question 14
I felt that way  all of the time = 1
I felt that way  most of the time = 2
I occasionally  felt that way  = 3
Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 37 of 39:
I rarely felt that way  = 4
I never felt that way  = 5
If at least one of Questions 12, 13 and 14 is not missing, then compute
Quality  of Life Score = 100*[(mean of Questions 12, 13 and 14 actuall y answered) –
1]/4
9.3.7 Social Limit ation
Code responses to each of Questions 15a
-d as follows:
Severel y limited = 1
Limited quite a bit = 2
Moderatel y limited = 3
Slightly  limited = 4
Did not limit at all = 5
Does not appl y or did not do for other reasons = <missing value>
If at least two o f Questions 15a- d are not missing, then compute
Social L imitation Score = 100*[(mean of Questions 15a -d actually  answered) –1]/4
9.3.8 Total Sy mptom Score
= mean of the following available summary  scores:
Symptom Frequency  Score
Symptom Burden Score
9.3.9 Overall Summary Score
= mean of the following available summary  scores:
Physical Limitation Score
Total Sy mptom Score
Quality  of Life Score
Social L imitation Score
9.3.10 Clinical Summary Score
= mean of the following available summary  scores:
Physical Limitation Score
Total Sy mptom Score
9.4 Combining inferences from multiple imputed data sets
With mimputations, mdifferent sets of the point and variance estimates for a parameter (in 
our case the contrast estimate) can be computed (see SAS version 9.2 Help for Proc 
Mianaly ze). Suppose that and   are the point and variance estimates, respectively , from 
the ith imputed data set, i= 1, 2, ..., m. Then the combined point estimate for from multiple 
imputation is the average of the mcomplete -data estimates: 

Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 38 of 39:
Suppose that is the within -imputation variance, which is the average of the mcomplete -
data estimates: 
And suppose that is the between -imputation variance: 
Then the variance estimate associated with isthe total variance [ 8]
The statistic is approximately  distributed as twith νmdegrees of freedom [14], 
where 
The degrees of freedom νmdepend on mand the ratio 
The ratio ris called the relative increase in variance due to nonresponse [8].When there is no 
missing information about , the values of rand Bare both zero. With a large value of mor a 
small value of r, the degrees of freedom νmwill be large and the distribution of 
will be approximately  normal. 
Another useful statistic is the fraction of missing information about : 
Both statistics rand λ are helpful diagnostics for assessing how the missing data contribute to 
the uncert ainty about . 
When the complete
-data degrees of freedom ν0are small, and there is only  a modest 
proportion of missing data, the computed degrees of freedom, νm, can be much larger than ν0, 
which is inappropriate. For example, with m=5and r=10%, the computed degrees of freedom 

Statistical Analysis Plan
Protocol No.: BAY 1067197 /15128 Page : 39 of 39:
νm=484 , which is inappropriate for data sets with complete -data degrees of freedom less than 
484. 
[14]recommend the use of adj usted degrees of freedom 
where    and   . 
Wewill 
specify  the complete -data degrees of freedom ν0with the EDF= option, the 
MIANALYZE procedure uses the adjusted degrees of freedom,   ∗, for inference. 
